Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Steve Nix is a member of the Society of American Foresters and a former forest resources analyst for the state of Alabama. Leaves are the food factories of the tree. Powered by sunlight, the green ...

Mar. 26, 2026 Deepfake X-rays created by AI are now convincing enough to fool both doctors and AI models. In tests, radiologists had limited success identifying fake images, especially when they ...